Notably, treatment of BRAFMT colorectal cancer cells with CH-223191 significantly reduced basal and BOLD-100-induced CYP1A1 mRNA levels and resulted in potent inhibition of ROS levels following BOLD-100 treatment [Fig. 6B–D; Supplementary Fig. S5D (bottom)]. Here, CYP1A1 is linked to colorectal cancer.